Literature DB >> 28404800

Racial differences in statin adherence following hospital discharge for ischemic stroke.

Karen C Albright1, Hong Zhao2, Justin Blackburn2, Nita A Limdi2, T Mark Beasley2, George Howard2, Vera Bittner2, Virginia J Howard2, Paul Muntner2.   

Abstract

OBJECTIVE: To compare nonadherence to statins in older black and white adults following an ischemic stroke.
METHODS: We studied black and white adults ≥66 years of age with Medicare fee-for-service insurance coverage hospitalized for ischemic stroke from 2007 to 2012 who filled a statin prescription within 30 days following discharge. Nonadherence was defined as a proportion of days covered <80% in the 365 days following hospital discharge. In addition, we evaluated factors associated with nonadherence for white and black participants separately.
RESULTS: Overall 2,763 beneficiaries met the inclusion criteria (13.5% black). Black adults were more likely than white adults to be nonadherent (49.7% vs 41.5%) even after adjustment for demographics, receipt of a low-income subsidy, and baseline comorbidities (adjusted relative risk [RR] 1.14, 95% confidence interval [CI] 1.01-1.29). Among white adults, receipt of a low-income subsidy (adjusted RR 1.13, 95% CI 1.02-1.26), history of coronary heart disease (adjusted RR 1.15, 95% CI 1.01-1.30), and discharge directly home following stroke hospitalization (adjusted RR 1.26, 95% CI 1.10-1.44) were associated with a higher risk of nonadherence. Among black adults, a 1-unit increase in the Charlson comorbidity index (adjusted RR 1.04, 95% CI 1.01-1.09), history of carotid artery disease (adjusted RR 2.38, 95% CI 1.08-5.25), and hospitalization during the 365 days prior to the index stroke (adjusted RR 1.34, 95% CI 1.01-1.78) were associated with nonadherence.
CONCLUSIONS: Compared with white adults, black adults were more likely to be nonadherent to statins following hospitalization for ischemic stroke.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28404800      PMCID: PMC5419984          DOI: 10.1212/WNL.0000000000003910

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Recent trends in cost-related medication nonadherence among stroke survivors in the United States.

Authors:  Deborah A Levine; Lewis B Morgenstern; Kenneth M Langa; John D Piette; Mary A M Rogers; Sudeep J Karve
Journal:  Ann Neurol       Date:  2013-02-22       Impact factor: 10.422

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

Review 3.  Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011.

Authors:  Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

4.  Full coverage for preventive medications after myocardial infarction.

Authors:  Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245

5.  Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction.

Authors:  Julie C Lauffenburger; Jennifer G Robinson; Christine Oramasionwu; Gang Fang
Journal:  Circulation       Date:  2013-12-10       Impact factor: 29.690

6.  Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data.

Authors:  Jessica C Young; Til Stürmer; Jennifer L Lund; Michele Jonsson Funk
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-03-15       Impact factor: 2.890

7.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

8.  Physician communication behaviors and trust among black and white patients with hypertension.

Authors:  Kimberly D Martin; Debra L Roter; Mary C Beach; Kathryn A Carson; Lisa A Cooper
Journal:  Med Care       Date:  2013-02       Impact factor: 2.983

9.  Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.

Authors:  Lisandro D Colantonio; Shia T Kent; Meredith L Kilgore; Elizabeth Delzell; Jeffrey R Curtis; George Howard; Monika M Safford; Paul Muntner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-29       Impact factor: 2.890

Review 10.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

View more
  9 in total

1.  Social Risk Factors for Medication Nonadherence: Findings from the CARDIA Study.

Authors:  Gabriela R Oates; Lucia D Juarez; Barbara Hansen; Catarina I Kiefe; James M Shikany
Journal:  Am J Health Behav       Date:  2020-03-01

2.  Ethnic Differences in 90-Day Poststroke Medication Adherence.

Authors:  Rebecca J Lank; Lynda D Lisabeth; Deborah A Levine; Darin B Zahuranec; Kevin A Kerber; Fatema Shafie-Khorassani; Erin Case; Belinda G Zuniga; George M Cooper; Devin L Brown; Lewis B Morgenstern
Journal:  Stroke       Date:  2019-05-14       Impact factor: 7.914

Review 3.  Interventions to Reduce Ethnic and Racial Disparities in Dyslipidemia Management.

Authors:  Andrew Y Chang; Nadeem E Abou-Arraj; Fatima Rodriguez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-05-07

4.  Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.

Authors:  Lisandro D Colantonio; Keri L Monda; Robert S Rosenson; Todd M Brown; Katherine E Mues; George Howard; Monika M Safford; Larisa Yedigarova; Michael E Farkouh; Paul Muntner
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727

5.  Issues in the Use of Human Tissues to Support Precision Medicine.

Authors:  William E Grizzle
Journal:  J Health Care Poor Underserved       Date:  2019

6.  Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System.

Authors:  Michael P Dorsch; Corey A Lester; Yuting Ding; Megan Joseph; Robert D Brook
Journal:  J Am Heart Assoc       Date:  2019-11-11       Impact factor: 5.501

7.  Association between CVDs and initiation and adherence to statin treatment in patients with newly diagnosed hypercholesterolaemia: a retrospective cohort study.

Authors:  In Sun Ryou; Jooyoung Chang; Joung Sik Son; Ahryoung Ko; Seulggie Choi; Kyuwoong Kim; Sung Min Kim; Sang Min Park
Journal:  BMJ Open       Date:  2021-04-07       Impact factor: 2.692

8.  Prescription smoking-cessation medication pharmacy claims after stroke and transient ischemic attack.

Authors:  Neal S Parikh; Yongkang Zhang; Daniel Restifo; Erika Abramson; Matthew J Carpenter; Babak B Navi; Hooman Kamel
Journal:  Prev Med Rep       Date:  2021-12-28

Review 9.  Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS.

Authors:  Lachlan L Dalli; Monique F Kilkenny; Isabelle Arnet; Frank M Sanfilippo; Doyle M Cummings; Moira K Kapral; Joosup Kim; Jan Cameron; Kevin Y Yap; Melanie Greenland; Dominique A Cadilhac
Journal:  Br J Clin Pharmacol       Date:  2022-05-22       Impact factor: 3.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.